Rayno Life Sciences Portfolio Update: MITI, QGEN, SGEN
Life Science Stocks are Stable in a Choppy Market; Macro Is Dominating The NASDAQ market stabilized today (but down 0.54%) after a two day sell-off that brought the qqq down to $57.79 from the $59.50 level last Thursday.The market skittishness was primarily caused by increasing concern about...
NYT Article Raises Issues with Genomics Tests with Cancer Patients
A front page article in the New York Times today by Gina Kolata, "How Bright Promise in Cancer Testing Fell Apart", chronicles a patient case study at Duke University about gene based tests for lung cancer. Additional commentary at other research institutions suggests that "good science has not...
Rayno Life Science Portfolio Tools and Dx-Big Winners YTD: CRA,CSII,EXAS,GPRO
Diagnostics is Still a Hot Ticket The Rayno Life Science Tools and Diagnostics Portfolio is up 12% YTD with big winners Celera up 31%, recently acquired by Quest Diagnostics (DGX), Cardiovascular Systems (CSII) up 32.5%,Exact Scientific (EXAS) up 42%, and GenProbe (GPRO) up 19.6%. In the news...
Rayno Life Science Portfolio Tools and Dx: Immucor (BLUD) Up 30% on Buyout
TPG Capital Offers $1.97B for diagnostic Company focused in blood donor screening. TPG Capital is a private equity firm with $48B in assets. Immucor was added to the Rayno Life Science Portfolio in April 2010 at a price of...
Rayno Life Science Portfolio 2011 H1 Update-Biopharm Big Winners:BIIB, CBST, REGN, SGEN
2011 A Huge Year for Life Science Investing As of mid-year the Rayno Life Science Biopharmaceutical Portfolio was up over 20% beating most ETF's and Life Science mutual funds. Our two recommended biotech ETF's for balancing and overweighting were FBT up 13.3% and IBB up 15.3%. Returns could...